$BAYRY

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

Orion posts strong Q1 with 17.8% revenue growth, 47.3% operating profit surge, and raises 2026 outlook. Pipeline advances boost investor confidence.

Global dermatomycoses market expected to grow significantly through 2035, driven by rising fungal infections and immunocompromised populations. Key players include Novartis, Bayer, and Sun Pharma.

SupplySide Connect NJ 2026 drew 260+ exhibitors focused on personalized health, longevity, and gut health. Expansion planned for Utah, Madison in 2027.

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.

Global regenerative agriculture market projected to grow from $3.86B in 2025 to $6.17B by 2030 at 9.78% CAGR, driven by startup-agribusiness alliances and data-driven solutions.

AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.

Blood plasma derivatives market to double to $104B by 2033, driven by rising disease prevalence and immunoglobulin demand across developed and emerging markets.

Bayer proposes $7.25 billion settlement to resolve thousands of Roundup cancer lawsuits, with payments spread over 21 years.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.